← boardnext 2026-10next 2026-10-31
ADAG
Advagene Biopharma Co. Ltd.distress 3/10 · well-funded / low risk$3.54-1%today-26% from 52w high
Oncology 1
Lead: Advanced/Metastatic Solid Tumors
Revenue
pre-revenue
Liquidity
$75M
Runway
4.8 yrs
Shares 1y
0%
Price & events
+74.1% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.3%
1D
-1.3%
1W
-11.2%
1M
-5.5%
3M
+42.0%
6M
+83.4%
1Y
+34.9%
2Y
-82.4%
5Y
-88.2%
All
Overview
- Market Cap
- $209.39M
- Enterprise Value
- $136.00M
- Volume
- 761
- 52 Week Range
- $1.41 – $4.78
- Total Shares
- 59.23M
- Float Shares
- 34.03M
- Short %
- 3.72%
- % Held by Insiders
- 21.61%
- % Held by Institutions
- 12.73%
- RVOL
- 0.00x
- Beta
- 0.58
Pipeline stages · 3 programs
AD17002
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
ADG126, Pembrolizumab (KEYTRUDA®), Standard of Care (Trifluridine/Tipiracil-Bevacizumab)
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
ADG206
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 3 trials · 2 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-10 Estimated 50% readout ~2026-11-15 | Phase 2 | AD17002 | Eosinophilic Asthma | — | not yet recruiting |
| 2026-10-31 Estimated 50% readout ~2026-12-15 | Phase 1/2 | ADG126, Pembrolizumab (KEYTRUDA®), Standard of Care (Trifluridine/Tipiracil-Bevacizumab) | Advanced/Metastatic Solid Tumors | — | recruiting |
| 2025-06-25 | Phase 1 | ADG206 | Advanced/Metastatic Solid Tumors | 14 | active not recruiting |
Catalyst news & presentations · 0
- No catalyst news yet.
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2026-04-06GuggenheimBuy
- 2025-11-24GuggenheimBuy
- 2025-09-18LUCID CAPITAL MARKETSBuy
- 2025-08-15HC Wainwright & Co.Buy
- 2025-08-06Leerink PartnersOutperform
- 2025-04-03HC Wainwright & Co.Buy
Competitors — Advanced/Metastatic Solid Tumors
- PFEPFIZER INC$142.2B · D3
Recent news
- 2026-07-18Adagene (ADAG) Morgan Stanley 22nd Annual Global Healthcare Conference Summary - Quartr
- 2026-07-18Adagene (ADAG) Leerink Global Healthcare Conference 2026 Summary - Quartr
- 2026-07-17Adagene (ADAG) H.C. Wainwright 26th Annual Global Investment Conference 2024 summary - Quartr
- 2026-07-17Adagene (ADAG) Oppenheimer 36th Annual Healthcare Life Sciences Conference summary - Quartr
- 2026-07-14Adagene (ADAG) Investor presentation Summary - Quartr
- 2026-07-14Guggenheim reiterates Adagene stock Buy rating on competitor shift - Investing.com UK
- 2026-07-14Guggenheim reiterates Adagene stock Buy rating on competitor shift - Investing.com
- 2026-07-08Adagene (ADAG) Stifel 2026 Targeted Oncology Virtual Forum Summary - Quartr
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.